12/23
09:17 am
livn
LivaNova to Present at J.P. Morgan Healthcare Conference in January [Yahoo! Finance]
Low
Report
LivaNova to Present at J.P. Morgan Healthcare Conference in January [Yahoo! Finance]
12/23
09:00 am
livn
LivaNova to Present at J.P. Morgan Healthcare Conference in January
Low
Report
LivaNova to Present at J.P. Morgan Healthcare Conference in January
12/22
06:00 am
livn
Cadence Neuroscience Announces Medical Device Veteran Daniel Moore as Independent Board Director
Low
Report
Cadence Neuroscience Announces Medical Device Veteran Daniel Moore as Independent Board Director
12/20
07:27 am
livn
LivaNova (NASDAQ:LIVN) was upgraded by analysts at KeyCorp to a "strong-buy" rating.
Low
Report
LivaNova (NASDAQ:LIVN) was upgraded by analysts at KeyCorp to a "strong-buy" rating.
12/19
07:47 am
livn
Building a More Inclusive Future: Mediaplanet Launches "Disability Empowerment" Campaign [Yahoo! Finance]
Low
Report
Building a More Inclusive Future: Mediaplanet Launches "Disability Empowerment" Campaign [Yahoo! Finance]
12/19
05:21 am
livn
At US$62.08, Is It Time To Put LivaNova PLC (NASDAQ:LIVN) On Your Watch List? [Yahoo! Finance]
Low
Report
At US$62.08, Is It Time To Put LivaNova PLC (NASDAQ:LIVN) On Your Watch List? [Yahoo! Finance]
12/18
09:02 pm
livn
LivaNova (NASDAQ:LIVN) is now covered by analysts at KeyCorp. They set an "overweight" rating on the stock.
Low
Report
LivaNova (NASDAQ:LIVN) is now covered by analysts at KeyCorp. They set an "overweight" rating on the stock.
12/17
08:24 am
livn
LivaNova (NASDAQ:LIVN) had its price target raised by analysts at Mizuho from $70.00 to $72.00. They now have an "outperform" rating on the stock.
Low
Report
LivaNova (NASDAQ:LIVN) had its price target raised by analysts at Mizuho from $70.00 to $72.00. They now have an "outperform" rating on the stock.
12/16
07:08 am
livn
LivaNova (NASDAQ:LIVN) was given a new $75.00 price target on by analysts at Robert W. Baird.
Low
Report
LivaNova (NASDAQ:LIVN) was given a new $75.00 price target on by analysts at Robert W. Baird.
12/9
04:25 pm
livn
LivaNova (NASDAQ:LIVN) had its "sell (d+)" rating reaffirmed by analysts at
Weiss Ratings.
Medium
Report
LivaNova (NASDAQ:LIVN) had its "sell (d+)" rating reaffirmed by analysts at
Weiss Ratings.
12/3
09:00 am
livn
LivaNova to Highlight Real-World Evidence from CORE-VNS Study and New Health Economics Analyses at American Epilepsy Society 2025 Annual Meeting
Low
Report
LivaNova to Highlight Real-World Evidence from CORE-VNS Study and New Health Economics Analyses at American Epilepsy Society 2025 Annual Meeting
12/3
04:51 am
livn
LivaNova Appoints Lucile Blaise as Global Head of Commercialization, Obstructive Sleep Apnea [Yahoo! Finance]
Low
Report
LivaNova Appoints Lucile Blaise as Global Head of Commercialization, Obstructive Sleep Apnea [Yahoo! Finance]
12/2
09:00 am
livn
LivaNova Appoints Lucile Blaise as Global Head of Commercialization, Obstructive Sleep Apnea
Low
Report
LivaNova Appoints Lucile Blaise as Global Head of Commercialization, Obstructive Sleep Apnea
11/28
09:35 pm
livn
A Look at LivaNova's (LIVN) Valuation Following Its Recent 20% Share Price Surge [Yahoo! Finance]
Low
Report
A Look at LivaNova's (LIVN) Valuation Following Its Recent 20% Share Price Surge [Yahoo! Finance]
11/26
02:11 pm
livn
LivaNova (NASDAQ:LIVN) had its "sell (d+)" rating reaffirmed by analysts at
Weiss Ratings.
Low
Report
LivaNova (NASDAQ:LIVN) had its "sell (d+)" rating reaffirmed by analysts at
Weiss Ratings.
11/25
09:43 am
livn
LivaNova to Present at Piper Sandler Healthcare Conference in December [Yahoo! Finance]
Low
Report
LivaNova to Present at Piper Sandler Healthcare Conference in December [Yahoo! Finance]
11/25
09:00 am
livn
LivaNova to Present at Piper Sandler Healthcare Conference in December
Medium
Report
LivaNova to Present at Piper Sandler Healthcare Conference in December
11/24
09:00 am
livn
LivaNova’s VNS Therapy for Drug-Resistant Epilepsy Procedures Receives Increased Provider Reimbursement from U.S. Centers for Medicare & Medicaid Services
Low
Report
LivaNova’s VNS Therapy for Drug-Resistant Epilepsy Procedures Receives Increased Provider Reimbursement from U.S. Centers for Medicare & Medicaid Services
11/13
08:11 am
livn
LivaNova (NASDAQ:LIVN) had its price target raised by analysts at Robert W. Baird from $63.00 to $70.00. They now have an "outperform" rating on the stock.
Low
Report
LivaNova (NASDAQ:LIVN) had its price target raised by analysts at Robert W. Baird from $63.00 to $70.00. They now have an "outperform" rating on the stock.
11/13
08:11 am
livn
LivaNova (NASDAQ:LIVN) had its price target raised by analysts at Mizuho from $65.00 to $70.00. They now have an "outperform" rating on the stock.
Low
Report
LivaNova (NASDAQ:LIVN) had its price target raised by analysts at Mizuho from $65.00 to $70.00. They now have an "outperform" rating on the stock.
11/12
03:53 pm
livn
LivaNova Delivers Strategic Roadmap and Long-Range Financial Plan at Investor Day [Yahoo! Finance]
Low
Report
LivaNova Delivers Strategic Roadmap and Long-Range Financial Plan at Investor Day [Yahoo! Finance]
11/12
03:26 pm
livn
LivaNova Delivers Strategic Roadmap and Long-Range Financial Plan at Investor Day
Low
Report
LivaNova Delivers Strategic Roadmap and Long-Range Financial Plan at Investor Day
11/9
12:43 am
livn
What LivaNova (LIVN)'s Q3 Revenue Growth and China Launch Mean For Shareholders [Yahoo! Finance]
Low
Report
What LivaNova (LIVN)'s Q3 Revenue Growth and China Launch Mean For Shareholders [Yahoo! Finance]
11/6
10:14 pm
livn
LivaNova PLC (LIVN) Q3 2025 Earnings Call Highlights: Strong Revenue Growth Amidst Margin Pressures [Yahoo! Finance]
Low
Report
LivaNova PLC (LIVN) Q3 2025 Earnings Call Highlights: Strong Revenue Growth Amidst Margin Pressures [Yahoo! Finance]
11/6
12:48 pm
livn
LivaNova (NASDAQ:LIVN) had its price target raised by analysts at Robert W. Baird from $61.00 to $63.00. They now have an "outperform" rating on the stock.
Low
Report
LivaNova (NASDAQ:LIVN) had its price target raised by analysts at Robert W. Baird from $61.00 to $63.00. They now have an "outperform" rating on the stock.